Management & BoD

Jim joined Ankrin Therapeutics as Chairman in February 2021. He also serves as Executive Chairman for Rewind Therapeutic. Before, Jim was Executive Chairman of Black Belt Tx and CEO of Karolinska Development, a publicly listed Nordic life science investment fund. Jim is Managing Director of bioskills, which he founded in 2013, offering strategic advice and hands-on management for entrepreneurs and investors. From 2001 to 2013, he worked as a Partner at Gimv focusing on life science investments. Before that, he was working as a senior scientist at the department of Oncology at Janssen Pharmaceutica, a J&J company. Jim holds a M.Sc. degree in Chemistry and Biochemistry from the University of Antwerp (Belgium) and a Ph.D. in Molecular and Cellular Biology from the University of Maastricht (The Netherlands).

Prof. Anja Groth holds a PhD in Molecular Biology from University of Copenhagen (2004) based on her research on genome stability at the Danish Cancer Society with Drs. Lukas and Bartek. From 2005 to 2007, she did postdoctoral research on epigenetics with Dr. Almouzni at Institut Curie, Paris. In 2008, Prof. Groth started a research group at Biotech Research and Innovation Centre (BRIC), University of Copenhagen, and in 2016 she was promoted to professor. She has received several prestigious awards, including the Danish Cancer Society Junior Research Prize (2011), the Heirloom Award for Women Scientist Leaders (2014) and the Elite Research Prize by the Danish Ministry of Higher Education and Science (2018). Prof. Groth was elected as a member of the Royal Danish Academy of Sciences and Letters in 2016 and EMBO in 2017 for her seminal work on epigenetics and genome stability. Prof. Groth has co-authored over 30 peer reviewed papers in top ranking scientific journals, including Science and Nature.

Dr. Ulrik Sørensen is a biotech entrepreneur and holds a PhD in medicinal chemistry and a management degree from Copenhagen Business School. Dr. Sørensen has 18+ years of experience from pharma and biotech. From 2002-2012 employed at NeuroSearch and as Head of Medicinal Chemistry and Project Director worked across strategic collaborations between biotech and big pharma. In 2011 Ulrik Sørensen co-founded the Danish biotech Acesion Pharma and led the company as CEO until 2016 in the successful building of the company and raising funds from Novo Holdings, SEED Capital, Innovation Fund Denmark, Broadview Ventures (US) and Wellcome Trust (UK), the latter as two separate awards (SDDI and Translational Award). Currently COO of Acesion Pharma and in 2016 awarded Ernst & Young Entrepreneur of the Year in Lifesciences.

Trine Bartholdy is a Portfolio Manager with BioInnovation Institute (BII.dk), a Copenhagen based Life Science Incubator. Prior of joining BII Trine has held Director positions in Venture Capital working at the Danish Growth Fund before moving to Sunstone Capital Life Science Ventures. During that time she worked with a broad range of early stage companies and indication areas, including oncology, and served on various BoD. Wanting to learn more about strategic drug development she joined Novo Nordisk where she worked with setting the strategic directions and Target Product Profiling for the early stage portfolio. Including evaluating M&A opportunities. Furthermore she has been the CEO of Maternity Foundation and DK CEO Fertility Partnership. Trine holds a M.Sc. in Finance and Accounting from CBS and a certificate in pharmaceutical drug development from Basel University Hospital (ECPM). Trine Bartholdy represents BII and holds an observer seat at Ankrin's BoD.

Dr. Ulrik Sørensen is a biotech entrepreneur and holds a PhD in medicinal chemistry and a management degree from Copenhagen Business School. Dr. Sørensen has 18+ years of experience from pharma and biotech. From 2002-2012 employed at NeuroSearch and as Head of Medicinal Chemistry and Project Director worked across strategic collaborations between biotech and big pharma. In 2011 Ulrik Sørensen co-founded the Danish biotech Acesion Pharma and led the company as CEO until 2016 in the successful building of the company and raising funds from Novo Holdings, SEED Capital, Innovation Fund Denmark, Broadview Ventures (US) and Wellcome Trust (UK), the latter as two separate awards (SDDI and Translational Award). Currently COO of Acesion Pharma and in 2016 awarded Ernst & Young Entrepreneur of the Year in Lifesciences.

Prof. Anja Groth holds a PhD in Molecular Biology from University of Copenhagen (2004) based on her research on genome stability at the Danish Cancer Society with Drs. Lukas and Bartek. From 2005 to 2007, she did postdoctoral research on epigenetics with Dr. Almouzni at Institut Curie, Paris. In 2008, Prof. Groth started a research group at Biotech Research and Innovation Centre (BRIC), University of Copenhagen, and in 2016 she was promoted to professor. She has received several prestigious awards, including the Danish Cancer Society Junior Research Prize (2011), the Heirloom Award for Women Scientist Leaders (2014) and the Elite Research Prize by the Danish Ministry of Higher Education and Science (2018). Prof. Groth was elected as a member of the Royal Danish Academy of Sciences and Letters in 2016 and EMBO in 2017 for her seminal work on epigenetics and genome stability. Prof. Groth has co-authored over 30 peer reviewed papers in top ranking scientific journals, including Science and Nature.

Dr. Frimurer holds a PhD (2000) in computational structural biology from University of Copenhagen. He has 15+ years of experience with structure-based chemical design technologies in academia and Pharma/Biotech. Following post-doctoral positions at Novo Nordisk A/S and Harvard University, Thomas Frimurer worked in positions as Principal Scientist at 7TM Pharma and at the NNF Center for Protein Research. Currently he is a co-founder of Ankrin Therapeutics and holds the position as Associate Professor at University of Copenhagen where he is head of a group focusing at Chemical and Molecular Receptology (computational chemistry).